An investigation on the nature of these therapeutic targets revealed a high diversity: Compounds directed against VEGF or the VEGFR were most frequently found, but there were also molecules directed against EGFR—a molecule prototypically mutated in subsets of adult glioblastoma [2]. The gene discussed is EGFR; the disease is glioblastoma.